- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756873
Etoricoxib in Ear Nose Throat Surgery
Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery
The aim of this study is to test the analgesic efficacy of etoricoxib (90 mg or 120 mg qd. perioperatively) for post-operative pain relief.
The primary endpoint is as follows:
- does preoperative etoricoxib reduce the post-operative opioid utilization in patients undergoing elective tonsillectomy under general anaesthesia (i.e. the post-operative opioid-sparing effect of etoricoxib in humans).
The secondary endpoints are as follows:
- does the etoricoxib medication have an impact on PONV or activities of daily
- does the etoricoxib medication influence the blood loss during surgery or the incidence of postoperative bleeding
- does the etoricoxib medication influence the operation time. In addition, adverse effects of etoricoxib will be documented.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
On day of surgery (day 0) the patients will be randomly assigned to one of the three groups using a sealed envelope method. The etoricoxib 90 mg group receives etoricoxib (Arcoxia®, Merck Sharp & Dohme GmbH, Haar, Germany) 90 mg orally, the etoricoxib 120 mg group receives etoricoxib 120 mg orally and the control group receives a placebo tablet orally 1 h before surgery (day 0). All patients receive a standard general anesthesia with intravenous propofol (2-3 mg/kg), fentanyl (2 µg/kg) and mivacurium (0.2 mg/kg) for induction. Patients are ventilated via a tracheal tube, anesthesia being maintained with sevoflurane (0.8 - 1.5% end-tidal concentration). If mean arterial blood pressure or heart rate increase to more than 25% above the pre-operative baseline value despite an end-tidal concentration of 1.5% sevoflurane, an intravenous bolus of fentanyl 0.05 mg will be administered. Monitoring includes electrocardiogram (ECG), non-invasive arterial blood pressure, pulse oximetry, end-tidal CO2 and end-tidal sevoflurane. On days 1 to 3 patients will receive etoricoxib (90 mg or 120 mg qd.) or placebo. After discharge on day 3, patients will receive etoricoxib (90 mg or 120 mg qd.) or placebo until cessation of pain during activity (swallowing). According to the current label for Arcoxia® 120 mg in Germany, patients taking etoricoxib 120 mg will switch to etoricoxib 90 mg on day 8. Rescue medication will be piritramid i.v. (day 0), oxycodone p.o. (day 1-2) and paracetamol p.o. (day 3-14).
Day -7 to -1: Inclusion/exclusion criteria, medical history, concomitant medications, laboratory, serum pregnancy test, informed consent Day 0: Study medication 1 h before surgery, intra-operative blood loss, pain score, opioid utilization, PONV score and anti-emetic medication Day 1: pain score, opioid utilization, PONV score, anti-emetic medication, bleeding Day 2: pain score, opioid utilization, PONV score, anti-emetic medication, bleeding Day 3: pain score, opioid utilization, PONV score, anti-emetic medication, bleeding Day 7: pain score, paracetamol utilization, bleeding Day 14: first day with no pain, last study medication, paracetamol utilization, bleeding
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Regensburg, Germany, 93053
- Universtiy Hospital Regensburg
-
Weiden i.d. OPf., Germany, 92637
- Weiden Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female patients
- 18 years of age
- female patients not pregnant/non-lactating
- indication for elective tonsillectomy
- written informed consent.
Exclusion Criteria:
- etoricoxib, other analgesic or anti-emetic medication within 10 half-lives
- evidence for active peptic ulceration
- history of gastrointestinal bleeding
- evidence of hepatic, renal or hematopoietic disorders
- heart failure (NYHA II-IV)
- uncontrolled arterial hypertension
- clinical evidence of arterial occlusive disease
- coronary heart disease or cerebrovascular disease
- inflammatory bowel disease
- hypersensitivity to analgetics, antipyretics, NSAIDs or antiemetics
- evidence for noncompliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
|
Placebo qd orally day 0-14
|
Experimental: 2
Etoricoxib 90 mg qd.
|
Etoricoxib 90 mg qd orally day 0-14
Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
|
Experimental: 3
Etoricoxib 120 mg qd.
(day 0-7) Etoricoxib 90 mg qd.
(day 8-14)
|
Etoricoxib 90 mg qd orally day 0-14
Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Post-operative opioid-sparing effect of etoricoxib in humans undergoing elective tonsillectomy
Time Frame: Day 0-3 after surgery
|
Day 0-3 after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Impact of etoricoxib medication on PONV or activities of daily or the incidence of postoperative bleeding
Time Frame: Day 0-14
|
Day 0-14
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- Etoric-TE-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tonsillectomy
-
Boston Children's HospitalTerminatedPost-tonsillectomy Pain | Post-tonsillectomy Activity | Post-tonsillectomy HydrationUnited States
-
IRCCS Burlo GarofoloRecruiting
-
Medtronic - MITGCompleted
-
University Children's Hospital BaselCompleted
-
Sarah KhanCompleted
-
Wayne State UniversityChildren's Hospital of Michigan FoundationUnknown
-
Centre Hospitalier Universitaire de BesanconCompleted
-
University of MichiganNational Institute on Drug Abuse (NIDA)CompletedDefault Dosing Settings for Opioid Prescriptions to Adolescents and Young Adults After TonsillectomyTonsillectomyUnited States
Clinical Trials on Administration of placebo
-
PurGenesis Technologies Inc.CompletedAtopic Dermatitis EczemaCanada
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
Camilo Jose Cela UniversityCompleted
-
Bionorica SECompletedCurrent SmokersBelgium
-
Federal University of UberlandiaFundação de Amparo à Pesquisa do estado de Minas GeraisCompletedHealth Behavior
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedAmyotrophic Lateral SclerosisSpain
-
Central Institute of Mental Health, MannheimCompletedChronic Lower Back Pain | Healthy Control SubjectsGermany
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
University Hospital, GhentCompletedVerrucae VulgaresBelgium
-
MWolztUnknown